Cellectis (CLLS) Non Operating Income (2015 - 2026)
Cellectis' (CLLS) quarterly Non Operating Income came in at -$7.4 million in Q1 2026, down 288.68% year-on-year from $3.9 million in Q1 2025, and down 143.52% quarter-over-quarter from $17.1 million in Q4 2025.
Cellectis (CLLS) Non Operating Income (2015 - 2026) Analysis & Trends
Cellectis' Non Operating Income history runs 12 years deep, the most recent figure standing at -$7.4 million for Q1 2026.
- On a quarterly basis, Non Operating Income fell 288.68% year-over-year to -$7.4 million in Q1 2026; TTM through Mar 2026 was -$11.9 million, a 2655.67% decrease from a year earlier, with the FY2025 full-year figure at -$34.9 million, down 253.29% from the prior year.
- Non Operating Income eased to -$7.4 million in Q1 2026 per CLLS's latest filing, from $17.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $26.3 million in Q1 2024 and bottomed at -$26.1 million in Q4 2023.
- The 5-year median for Non Operating Income is -$4.4 million (2023), against an average of -$1.7 million.
- Across the five-year window, Non Operating Income sank 737.74% in 2022 and soared 696.89% in 2024, its largest moves.
- Year by year, Non Operating Income stood at -$20.0 million in 2022, then tumbled by 30.87% to -$26.1 million in 2023, then soared by 165.54% to $17.1 million in 2024, then changed by 0.0% to $17.1 million in 2025, then sank by 143.52% to -$7.4 million in 2026.
- Per Business Quant, the three latest CLLS Non Operating Income figures stand at -$7.4 million (Q1 2026), $17.1 million (Q4 2025), and -$7.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Cellectis | 285.50 Mn | 99.83 Mn | - | -7.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.45 Mn |
| Dec 31, 2025 | 17.12 Mn |
| Sep 30, 2025 | -7.45 Mn |
| Jun 30, 2025 | -14.15 Mn |
| Mar 31, 2025 | 3.95 Mn |
| Dec 31, 2024 | 17.12 Mn |
| Sep 30, 2024 | -12.35 Mn |
| Jun 30, 2024 | -8.25 Mn |
| Mar 31, 2024 | 26.28 Mn |
| Dec 31, 2023 | -26.12 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | -5.84 Mn |
| Mar 31, 2023 | -4.40 Mn |
| Dec 31, 2022 | -19.96 Mn |
| Sep 30, 2022 | 1.81 Mn |
| Jun 30, 2022 | 8.30 Mn |
| Mar 31, 2022 | -912,000.00 |
| Dec 31, 2021 | 3.13 Mn |
| Sep 30, 2021 | 2.30 Mn |
| Jun 30, 2021 | -4.13 Mn |